Status:
UNKNOWN
TL-895 and KRT-232 Study in Acute Myeloid Leukemia
Lead Sponsor:
Telios Pharma, Inc.
Collaborating Sponsors:
Kartos Therapeutics, Inc.
Conditions:
Acute Myeloid Leukemia
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
This study evaluates TL-895, a potent, orally available and highly selective irreversible tyrosine kinase inhibitor combined with navtemadlin (KRT-232), a novel oral small molecule inhibitor of MDM2 f...
Eligibility Criteria
Inclusion
- TP53 wildtype AML
- Relapsed/Refractory to at least one prior therapy, one of which must have included a FLT-3 inhibitor
- FLT3 mutation (FLT3-TKD or FLT3-ITD)
- ECOG 0-2
- Adequate hematologic, hepatic, and renal functions
Exclusion
- AML subtype 3
- Prior treatment with MDM2 antagonist therapies
- Eligible for HSCT
Key Trial Info
Start Date :
March 31 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2025
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT04669067
Start Date
March 31 2021
End Date
November 1 2025
Last Update
February 17 2023
Active Locations (35)
Enter a location and click search to find clinical trials sorted by distance.
1
Keck School of Medicine
Los Angeles, California, United States, 90033
2
University of California, Irvine Medical Center
Orange, California, United States, 92868
3
Georgia Cancer Center
Augusta, Georgia, United States, 30912
4
Northwestern Memorial Hospital
Chicago, Illinois, United States, 60611